Shanghai preclinical CRO providing drug-safety and toxicology testing services to Chinese and global pharma developers.
Shanghai preclinical CRO providing drug-safety and toxicology testing services to Chinese and global pharma developers.
Is paid per study by drug developers who need toxicology and safety testing before human trials, so revenue follows the number and size of studies it wins, and long-running programmes bring repeat work from the same clients. Laboratories certified to good laboratory practice, the standard regulators require, are its core assets.
In one line: A small Chinese Charles River Labs (toxicology arm).
Moat: narrow (regulatory licence, installed base). GLP-certified lab facilities and accumulated regulatory track record are slow for new entrants to replicate.
Headquarters: Shanghai, China · Employees: 1,173
Size Shanghai InnoStar Bio-tech (688710.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1,000M, the 2162nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥75.86 on 18 Nov 2026.
Performance Over six months the shares gained 17.3%, against -11.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 23.8% over the last twelve months (peer median +7.1%); the operating margin is 6.4% (peer median 12.9%).
Valuation It trades at 59.3× forward earnings against a peer median of 18.3× (2nd most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 6 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.03B | CN¥811M | CN¥1.14B | CN¥1.04B | CN¥863M |
| Revenue growth | — | -29% | +10% | +20% | — |
| Gross profit | CN¥377M | CN¥193M | CN¥368M | CN¥438M | CN¥333M |
| EBITDA | n/a | CN¥40.7M | CN¥211M | CN¥269M | CN¥186M |
| Net income | CN¥78.3M | -CN¥30.5M | CN¥148M | CN¥194M | CN¥135M |
| Free cash flow | CN¥207M | -CN¥32.6M | -CN¥384M | -CN¥65.8M | CN¥133M |
| Capital expenditure | CN¥179M | CN¥134M | CN¥288M | CN¥234M | CN¥146M |
| Total debt | CN¥122M | CN¥116M | CN¥236M | CN¥255M | CN¥248M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai InnoStar Bio-tech 688710.SS | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 26.2× | 25.6% |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
| Joinn Laboratories (China) 603127.SS | $3.67B | -6% | +12% | -4% | 29.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688710.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.5% | -5.0% | 5th lowest of 21 |
| 6-month return | +17.3% | -11.5% | 4th highest of 21 |
| Distance from 52-week high | -32.3% | -32.2% | 11th highest of 21 |
| Revenue growth (TTM) | +23.8% | +7.1% | 5th highest of 18 |
| Operating margin | 6.4% | 12.9% | 6th lowest of 18 |
| Forward P/E | 59.3× | 18.3× | 2nd most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 12.7% | 3.3% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +19.4% | +5.6% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -6.7 pp | -3.5 pp | 5th least demanding of 13 |
| ROIC minus cost of capital | +3.8 pp | -0.2 pp | 7th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |